Hypothesis

Corrected sleep latency estimates from consumer sleep trackers, adjusted for device type and individual physiology (BMI, sleep efficiency, AHI), can be used to time morning blue‑light exposure so that each individual receives light at their optimal circadian phase, resulting in greater phase advance and improved sleep outcomes than standard fixed‑timing recommendations.

Mechanistic Rationale

• Consumer trackers show systematic biases: wearables slightly underestimate latency (‑0.81 min) while nearables overestimate it (+29.02 min) [1].
• Morning blue‑light (460‑480 nm) advances the circadian phase via ipRGC‑SCN signaling; the magnitude of advance depends on the circadian time of exposure, with the largest shifts occurring in the late biological night/early morning [2,3].
• If a tracker overestimates sleep latency, a prescribed “lights-on at 7 am” may actually be delivered later relative to the individual’s true circadian phase, reducing the effective phase advance.
• Conversely, underestimation could lead to light being given too early, potentially causing phase delays or minimal effect.
• Individual factors (BMI, sleep efficiency, AHI) modulate tracker accuracy for sleep stage estimation, suggesting they also affect latency bias [1]. Incorporating these covariates into a correction model should yield a more accurate estimate of the time of sleep onset, allowing light to be timed to the true biological morning.

Testable Predictions

1. Applying a device‑specific correction algorithm to raw sleep latency data will reduce the mean absolute error between estimated and polysomnographically measured sleep onset to <5 min across device types.
2. Participants receiving morning blue‑light exposure timed according to corrected sleep latency will exhibit a significantly larger dim‑light melatonin onset (DLMO) advance (≥15 min greater) than those receiving light at a fixed clock time (e.g., 7:00 am).
3. The corrected‑timing group will show improved next‑day sleep efficiency (>85 %) and reduced subjective sleep latency compared with the control group.
4. The magnitude of benefit will correlate with baseline tracker bias (larger bias → larger improvement).

Proposed Experiment

• Design: Parallel‑group, randomized controlled trial (n = 120) stratified by tracker type (wearable vs nearable) and baseline BMI.
• Procedure: All participants wear their assigned tracker for a baseline week to collect raw latency data. A multivariable regression model (using device type, BMI, sleep efficiency, AHI) predicts the correction factor. The experimental group receives 30 min of 460‑480 nm light each morning, timed to the corrected sleep onset + 30 min (i.e., light starts 30 min after estimated sleep offset). The control group receives the same light duration at a fixed 7:00 am clock time, regardless of tracker data.
• Outcome Measures: DLMO assessed via salivary melatonin on nights 0 and 7; actigraphy‑derived sleep latency and efficiency; sleep‑diary scores.
• Analysis: ANCOVA testing group differences in DLMO change, adjusting for baseline DLMO and tracker bias.

If the hypothesis holds, this work would demonstrate that accounting for tracker‑specific and individual biases transforms raw consumer data into a actionable circadian‑health tool, closing the loop between monitoring and intervention.

References

[1] Mhealth Jmir 2023 validation of consumer sleep trackers. https://mhealth.jmir.org/2023/1/e50983 [2] Morning blue light phase advance study. https://www.tandfonline.com/doi/full/10.1080/07420528.2018.1527773 [3] Low‑level morning light efficacy. https://pubmed.ncbi.nlm.nih.gov/36058557/ [4] Evening screen‑time melatonin suppression. https://www.chronobiologyinmedicine.org/m/journal/view.php?number=167 [5] Blue‑depleted lighting mitigation. https://pmc.ncbi.nlm.nih.gov/articles/PMC7065627/ [6] Genetic vulnerability to evening light. https://pmc.ncbi.nlm.nih.gov/articles/PMC9424753/